Brokers Offer Predictions for CG Oncology FY2025 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of CG Oncology in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($1.52) per share for the year. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06. The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.30 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%.

Several other equities research analysts have also issued reports on the stock. Bank of America reissued a “buy” rating and issued a $65.00 price objective on shares of CG Oncology in a research report on Tuesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of CG Oncology in a report on Friday, January 10th. Royal Bank of Canada restated an “outperform” rating and set a $66.00 price objective on shares of CG Oncology in a research note on Friday, December 6th. TD Cowen assumed coverage on CG Oncology in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Finally, UBS Group assumed coverage on CG Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $60.00 price target on the stock. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, CG Oncology has a consensus rating of “Buy” and a consensus target price of $63.88.

CG Oncology Stock Performance

CG Oncology stock opened at $30.21 on Thursday. CG Oncology has a 12 month low of $25.77 and a 12 month high of $50.23. The stock’s 50-day moving average is $31.05 and its 200-day moving average is $34.13.

Insider Buying and Selling at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $29.66, for a total value of $29,660.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Hong Fang Song sold 700,000 shares of CG Oncology stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $28.00, for a total transaction of $19,600,000.00. Following the completion of the sale, the director now owns 3,003,931 shares of the company’s stock, valued at $84,110,068. This trade represents a 18.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 702,000 shares of company stock worth $19,664,200.

Hedge Funds Weigh In On CG Oncology

Institutional investors have recently bought and sold shares of the stock. Amalgamated Bank increased its holdings in shares of CG Oncology by 107.6% during the 3rd quarter. Amalgamated Bank now owns 1,621 shares of the company’s stock valued at $61,000 after acquiring an additional 840 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CG Oncology during the third quarter valued at approximately $241,000. Profund Advisors LLC bought a new position in shares of CG Oncology in the second quarter valued at approximately $300,000. HighVista Strategies LLC acquired a new stake in shares of CG Oncology in the third quarter worth $594,000. Finally, M&T Bank Corp boosted its holdings in shares of CG Oncology by 55.7% during the 3rd quarter. M&T Bank Corp now owns 16,758 shares of the company’s stock worth $632,000 after buying an additional 5,996 shares during the period. 26.56% of the stock is currently owned by institutional investors.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.